Hear American virologist Robert Gallo speaking about the prospects in the development of HIV vaccine
Hear American virologist Robert Gallo speaking about the prospects in the development of HIV vaccine
American virologist Robert Gallo, speaking in 2011 to discuss HIV and the prospects for a vaccine.
University College Cork, Ireland (A Britannica Publishing Partner)
Transcript
ROBERT GALLO: I'm Robert Gallo, usually called Bob. And I'm director of the Institute of Human Virology, University of Maryland in Baltimore. I was formerly at the National Cancer Institute, National Institute of Health in Bethesda, Maryland, for 30 years. And 15 years as director of this new institute.
I was invited to give this lecture while I was in Ireland. And people know that I'm going to spend a few days when I'm here, you know, hunting around the south, and well, not just the south-- both sides, for a few days. And I have friends here. And I will attend a meeting in Dublin in a few days. And also, I had contact with Rosarii Griffin before and the director of the Center for Global Development. And I want to be supportive to this idea in any way I can.
Well, yeah, well, the lecture, I'm going to talk about viruses generally and some of the current threats by viruses. Then I'll focus on the viruses I was involved in called retroviruses. The first was a leukemia-causing virus, unusual leukemia for this part of the world but common in some other parts. And that that led us, because it was what we suspected would be a related virus, but with different final properties, to the AIDS virus, that the AIDS virus is also a retrovirus with some sort of relationship to the leukemia virus.
And the leukemia virus led us to think about this same category of virus as the cause of AIDS and got me started early on in AIDS with the idea in 1982 to search for this kind of virus. The progress that science has made in AIDS and in some other epidemic diseases and the science that we kind of need to solve the problem, and a big part of that is, indeed, the vaccine, as you asked.
It's very, very difficult for a scientist who wants to be optimistic to tell you we're X years, X months, away from an effective vaccine. Let me say to you that throughout the history of vaccine research, it's extremely difficult with HIV for reasons that are complicated. It's easy to tell a listener, it's because there's a lot of variation in the virus. That's true of influenza and many other viruses. This has maybe a little more variation.
The big problem with this virus is that it puts its genes in the cell that it infects, into the DNA chromosome forever. So when that cell divides, virus genes are transmitted. So the individual is infected a lifetime. And that happens within 24 hours of exposure to the virus. So it is-- I won't go into the whys, except in the talk-- a tremendous challenge. You have to block every cell virtually from getting infected right at the start.
And the principles were not really well thought out an earlier vaccine trials, which failed. And for me, honestly, they were predictable failures. But recently, the Sanofi-Aventis, a pharmaceutical company, with major collaboration from Walter Reed Army Hospital in the Washington, DC area, scientists from there, and in further collaborations with people in Thailand, have a trial that had a little bit of success.
My colleagues and myself think we know why it had a little success and why it wasn't more. We think the kind of antibodies they generated don't last very long. And we think, kind of unwittingly, they made the kind of vaccine that we're deliberately trying to develop for producing a certain kind of antibody that tends to block at the gate-- in other words, as the virus is coming into the cell.
But these antibodies don't last very long. And I'm sure the levels that they produced in their trial were not that high. So they got a hint and more than a hint of some success, especially early, when the antibodies were there. So we have a major collaboration with them now, with our vaccine coupled with this one, sponsored by the Gates Foundation. And I hope within a year, we are in the clinic, which means the first phase to be sure you're not anything harmful, and then eventually to really testing extensively.
Am I optimistic about it? I'm enthusiastic about this approach. I recognize we haven't solved the problem of getting these antibodies to last. I'm gambling and hoping that as we go into the first phase of this, that in that year or two, we'll solve the problem and bring it forward quickly.
INTERVIEWER: That's great.
I was invited to give this lecture while I was in Ireland. And people know that I'm going to spend a few days when I'm here, you know, hunting around the south, and well, not just the south-- both sides, for a few days. And I have friends here. And I will attend a meeting in Dublin in a few days. And also, I had contact with Rosarii Griffin before and the director of the Center for Global Development. And I want to be supportive to this idea in any way I can.
Well, yeah, well, the lecture, I'm going to talk about viruses generally and some of the current threats by viruses. Then I'll focus on the viruses I was involved in called retroviruses. The first was a leukemia-causing virus, unusual leukemia for this part of the world but common in some other parts. And that that led us, because it was what we suspected would be a related virus, but with different final properties, to the AIDS virus, that the AIDS virus is also a retrovirus with some sort of relationship to the leukemia virus.
And the leukemia virus led us to think about this same category of virus as the cause of AIDS and got me started early on in AIDS with the idea in 1982 to search for this kind of virus. The progress that science has made in AIDS and in some other epidemic diseases and the science that we kind of need to solve the problem, and a big part of that is, indeed, the vaccine, as you asked.
It's very, very difficult for a scientist who wants to be optimistic to tell you we're X years, X months, away from an effective vaccine. Let me say to you that throughout the history of vaccine research, it's extremely difficult with HIV for reasons that are complicated. It's easy to tell a listener, it's because there's a lot of variation in the virus. That's true of influenza and many other viruses. This has maybe a little more variation.
The big problem with this virus is that it puts its genes in the cell that it infects, into the DNA chromosome forever. So when that cell divides, virus genes are transmitted. So the individual is infected a lifetime. And that happens within 24 hours of exposure to the virus. So it is-- I won't go into the whys, except in the talk-- a tremendous challenge. You have to block every cell virtually from getting infected right at the start.
And the principles were not really well thought out an earlier vaccine trials, which failed. And for me, honestly, they were predictable failures. But recently, the Sanofi-Aventis, a pharmaceutical company, with major collaboration from Walter Reed Army Hospital in the Washington, DC area, scientists from there, and in further collaborations with people in Thailand, have a trial that had a little bit of success.
My colleagues and myself think we know why it had a little success and why it wasn't more. We think the kind of antibodies they generated don't last very long. And we think, kind of unwittingly, they made the kind of vaccine that we're deliberately trying to develop for producing a certain kind of antibody that tends to block at the gate-- in other words, as the virus is coming into the cell.
But these antibodies don't last very long. And I'm sure the levels that they produced in their trial were not that high. So they got a hint and more than a hint of some success, especially early, when the antibodies were there. So we have a major collaboration with them now, with our vaccine coupled with this one, sponsored by the Gates Foundation. And I hope within a year, we are in the clinic, which means the first phase to be sure you're not anything harmful, and then eventually to really testing extensively.
Am I optimistic about it? I'm enthusiastic about this approach. I recognize we haven't solved the problem of getting these antibodies to last. I'm gambling and hoping that as we go into the first phase of this, that in that year or two, we'll solve the problem and bring it forward quickly.
INTERVIEWER: That's great.